Skip to main content
Clinical Trials/NCT06095180
NCT06095180
Not yet recruiting
Not Applicable

Comparison of Efficacy of Ultrasound-Guided Steroid Injection and Dry Needling in Piriformis Muscle Syndrome

Gaziler Physical Medicine and Rehabilitation Education and Research Hospital0 sites60 target enrollmentNovember 28, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Piriformis Muscle Syndrome
Sponsor
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Enrollment
60
Primary Endpoint
Visual Analog Scale (VAS) (Resting)
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to to compare its effectiveness ultrasound-guided steroid injection, dry needling treatments and exercises in patients diagnosed with piriformis syndrome.

Detailed Description

Piriformis syndrome is a painful entrapment neuropathy caused by compression of the sciatic nerve under the piriformis muscle. The most common cause is myofascial pain syndrome. There is no gold standard treatment for piriformis syndrome. The main purpose of treatment methods is to reduce local pain, muscle tension and spasm. This work; it will contribute to the literature by comparing steroid, dry needling and exercise treatments in patients with piriformis syndrome.

Registry
clinicaltrials.gov
Start Date
November 28, 2023
End Date
August 26, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Yasin Demir

Associate Professor

Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • Age between 18-60,
  • Hip pain for ≥1 month
  • Local piriformis pain with prolonged sitting (\>20 minutes) and increased sensitivity
  • Patients with suspected piriformis syndrome based on clinical maneuvers
  • Signing and informed consent from showing consent to participate in the study

Exclusion Criteria

  • Hip surgery
  • Lumbar disc disease
  • History of inflammatory hip disease
  • Medical treatment for pain is started
  • Neurological deficit
  • Breastfeeding or pregnant
  • Allergy to local anesthetic
  • Use of anticoagulants
  • Body mass index \>35
  • Active psychiatric illness

Outcomes

Primary Outcomes

Visual Analog Scale (VAS) (Resting)

Time Frame: at baseline and change from baseline VAS (resting) at 4 weeks and 12 weeks

Average hip pain intensity at rest over the past week is a visual analog scale. (VAS; ranging from 0 to 10, 0 = no pain and 10 = worst possible pain)

Visual Analogue Scale (VAS) (Sitting)

Time Frame: at baseline and change from baseline VAS (sitting) at 4 weeks and 12 weeks

Average hip pain intensity in a sitting position over the past 24 hours, a visual analog scale. (VAS; ranging from 0 to 10, 0 = no pain and 10 = worst possible pain)

Visual Analog Scale (VAS) (Movement)

Time Frame: at baseline and change from baseline VAS (movement) at 4 weeks and 12 weeks

Average hip pain intensity during movement over the past 1 week is a visual analog scale. (VAS; ranging from 0 to 10, 0 = no pain and 10 = worst possible pain)

Secondary Outcomes

  • Oswestry disability index (ODI)(at baseline and change from baseline ODI at 4 weeks and 12 weeks)

Similar Trials